71897-07-9
71897-07-9
Chemical Structure
AG 1295
- CAS No.: 71897-07-9
- Formula:C16H14N2
- Molecular Weight:234.30
IUPAC Name: 6,7-dimethyl-2-phenylquinoxaline
InChIKey: FQNCLVJEQCJWSU-UHFFFAOYSA-N
SMILES: CC1=C(C)C=C2N=CC(C3=CC=CC=C3)=NC2=C1
Biological Activity: AG 1295 is a selective platelet-derived growth factor receptor (PDGFR) tyrosine-kinase inhibitor. AG1295 abolishes autophosphorylation of the PDGFR whereas not affects the autophosphorylation of the EGF receptor[1][2][3][4].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
AG 1295 | 99.86% | AG 1295 is a selective platelet-derived growth factor receptor (PDGFR) tyrosine-kinase inhibitor. AG1295 abolishes autophosphorylation of the PDGFR whereas not affects the autophosphorylation of the EGF receptor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AG 1295 (Standard) | ≥98% | AG 1295 (Standard) is the analytical standard of AG 1295. This product is intended for research and analytical applications. AG 1295 is a selective platelet-derived growth factor receptor (PDGFR) tyrosine-kinase inhibitor. AG1295 abolishes autophosphorylation of the PDGFR whereas not affects the autophosphorylation of the EGF receptor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fc 11a-2 | 99.75% | Fc 11a-2, a benzimidazole compound, is an orally active and potent NLRP3 inflammasome inhibitor. Fc 11a-2 restrains the formation of NLRP3 inflammasome by inhibiting activation of caspase-1 and thus the activation of IL-1b/IL-18. Fc 11a-2 prevents the development of Dextran sulfate sodium (DSS; HY-116282C)-induced murine experimental colitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
2-Methyl-3-phenylquinoxaline | 98.70% | 2-Methyl-3-phenylquinoxaline (compound 38) is a potent platelet-derived growth factor receptor tyrosine kinase (PDGF-RTK) inhibitor with modest inhibitory activity against PDGFR kinase in intact cells (IC50 greater than 100 μM). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tyrphostin AG1433 | 98.24% | Tyrphostin AG1433 (SU1433) is a tyrosine kinases inhibitor. AG1433 is also a selective PDGFRβ and VEGFR-2 (Flk-1/KDR) inhibitor with IC50s of 5.0 μM and 9.3 μM, respectively. Tyrphostin AG1433 prevents blood vessel formation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tyrphostin AG1433 hydrochloride | Tyrphostin AG 1433 is a specific and potent inhibitor of PDGFR-β and of KDR/Flk-1. Tyrphostin AG 1433 acts as an angiogenesis inhibitor. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CA77.1 | 99.92% | CA77.1 is a potent, brain-penetrant and orally active chaperone-mediated autophagy (CMA) activator with favorable pharmacokinetics. CA77.1 is a derivative of AR7 (HY-101106) and can increase the expression of the lysosomal receptor LAMP2A in?lysosomes. CA77.1 improves behavior and neuropathology in PS19 mice model and can be used for alzheimer's?disease research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PAQ | PAQ (Compound 4c) is a quinoxaline derivative. PAQ is an orally active neuroprotective agent, which targets dopamine (DA) neurons and activates reticulum endoplasmic ryanodine receptor (RyR) channels, without effects on glia cells. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Tyrphostin AG1296 (Standard) | ≥98% | Tyrphostin AG1296 (Standard) is the analytical standard of Tyrphostin AG1296. This product is intended for research and analytical applications. Tyrphostin AG1296 is a potent and selective inhibitor of platelet-derived growth factor receptor (PDGFR), with an IC50 of 0.8 μM. Tyrphostin AG1296 inhibits signaling of human PDGF α- and β-receptors as well as of the related stem cell factor receptor (c-Kit). Tyrphostin AG1296 is also a potent inhibitor of FLT3, with an IC50 in the micromolar range. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ecMetAP-IN-1 | 98.12% | ecMetAP-IN-1 is an inhibitor of E. coli methionine aminopeptidase (ecMetAP) with an IC50 of 2.086 μM. ecMetAP-IN-1 is applicable to research related to bacterial infections caused by E. coli. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
(2-Phenylquinolin-7-yl)methanol | 98.82% | (2-Phenylquinolin-7-yl)methanol is a drug intermediate for synthesis of various active compounds. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BF-170 | 99.74% | BF-170 is a selective tau fibril binding agent with an EC50 of 221 nM. It exhibits good blood-brain barrier permeability, and after intravenous injection in mice, the concentration in brain tissue reaches 9.1% ID/g within 2 minutes (with a brain clearance rate of 0.25% ID/g after 30 minutes). BF-170 can be used as a probe for tau protein pathology imaging in Alzheimer's disease (AD). It plays an important role in early-stage AD research and holds potential for imaging studies of tau-related neurodegenerative diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kovalenko M, et al. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res. 1994 Dec 1;54(23):6106-14. [Content Brief]
- [2]. Zheng Y, et al. Platelet-derived growth factor receptor kinase inhibitor AG1295 and inhibition of experimental proliferative vitreoretinopathy. Jpn J Ophthalmol. 2003 Mar-Apr;47(2):158-65. [Content Brief]
- [3]. Inhibition of aortic allograft vasculopathy by local delivery of platelet-derived growth factor receptor tyrosine-kinase blocker AG-1295. Transplantation. 2002 Nov 15;74(9):1335-41. [Content Brief]
- [4]. Ludewig D, et al. PDGF receptor kinase blocker AG1295 attenuates interstitial fibrosis in rat kidney after unilateral obstruction. Cell Tissue Res. 2000 Jan;299(1):97-103. [Content Brief]
